Price Disclosure Reductions for 2022 April Cycle
This summary only includes medicines taking a price disclosure reduction on 1 April 2022. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes below show percentage (%) price differences and Approved Ex-Manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.
Flow-on Reductions for F2 Combination Items
Responsible persons with a brand of an F2 combination item should note that:
- if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2022 if the price of a component ingredient is also reduced and flowing on this component price reduction results in a lower price; or
- if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.
Outcomes for flow-on price disclosure reductions to F2 combination items have been communicated to responsible persons with brands of affected drugs.
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands listed in Schedule 2 of the determination will not take a price disclosure reduction.
Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2021 will also take the reduction on 1 April 2022 under section 99ADHA of the Act.
An industry agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process
The date for lodgement of disputes was by 5:00pm AEST on 17 December 2021.
Indicative prices for 1 April 2022 (including price to pharmacy, dispensed price for maximum quantity and price premiums) were published in January 2022.
Final prices for 1 April 2022 reductions (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from March 2022.
2022 April Cycle Outcomes Summary
| Legal Instrument Drug | Legal Instrument MoA | Legal Instrument Form | Average AEMP |
WAPD (%) (Drug/MoA) |
WADP potential April '22 AEMP |
October '21 AEMP | Percentage difference between October '21 and April '22 AEMP |
Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed Does not meet 30 month clock |
Unadjusted Price Reduction threshold (%) |
|---|---|---|---|---|---|---|---|---|---|
| Acamprosate | Oral | Tablet (enteric coated) containing acamprosate calcium 333 mg | $95.53 | 25.66% | $71.02 | $84.63 | 16.08% | GWAPD | 10 |
| Alendronic acid with colecalciferol and calcium | Oral | Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate) | $10.92 | 77.56% | $2.45 | $10.92 | 77.56% | OWAPD | 30 |
| Arsenic | Injection | Injection concentrate containing arsenic trioxide 10 mg in 10 mL | $2,435.03 | 49.01% | $1,241.62 | $2,435.03 | 49.01% | Does not meet 30 month clock | 10 |
| Buprenorphine | Transdermal | Transdermal patch 10 mg | $20.42 | 15.31% | $17.29 | $20.42 | 15.33% | GWAPD | 10 |
| Buprenorphine | Transdermal | Transdermal patch 15 mg | $25.96 | 15.31% | $21.99 | $25.96 | 15.29% | GWAPD | 10 |
| Buprenorphine | Transdermal | Transdermal patch 20 mg | $31.51 | 15.31% | $26.69 | $31.51 | 15.30% | GWAPD | 10 |
| Buprenorphine | Transdermal | Transdermal patch 25 mg | $36.76 | 15.31% | $31.13 | $36.76 | 15.32% | GWAPD | 10 |
| Buprenorphine | Transdermal | Transdermal patch 30 mg | $42.01 | 15.31% | $35.58 | $42.01 | 15.31% | GWAPD | 10 |
| Buprenorphine | Transdermal | Transdermal patch 40 mg | $52.51 | 15.31% | $44.47 | $52.51 | 15.31% | GWAPD | 10 |
| Buprenorphine | Transdermal | Transdermal patch 5 mg | $11.34 | 15.31% | $9.60 | $11.34 | 15.34% | GWAPD | 10 |
| Cabazitaxel | Injection | Concentrated injection 60 mg (as acetone solvate) in 1.5 mL, with diluent | $946.16 | 37.08% | $595.32 | $946.16 | 37.08% | Does not meet 30 month clock | 10 |
| Cabazitaxel | Injection | Solution concentrate for I.V. infusion 60 mg in 6 mL | $946.16 | 37.08% | $595.32 | $946.16 | 37.08% | Does not meet 30 month clock | 10 |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 160 mg in 8 mL | $48.24 | 30.86% | $33.35 | $48.24 | 30.87% | OWAPD | 30 |
| Docetaxel | Injection | Solution concentrate for I.V. infusion 80 mg in 4 mL | $24.12 | 30.86% | $16.68 | $24.12 | 30.85% | OWAPD | 30 |
| Erlotinib | Oral | Tablet 100 mg (as hydrochloride) | $669.02 | 20.56% | $531.47 | $669.02 | 20.56% | Does not meet 30 month clock | 10 |
| Erlotinib | Oral | Tablet 150 mg (as hydrochloride) | $827.66 | 20.56% | $657.49 | $827.66 | 20.56% | Does not meet 30 month clock | 10 |
| Erlotinib | Oral | Tablet 25 mg (as hydrochloride) | $184.33 | 20.56% | $146.43 | $184.33 | 20.56% | Does not meet 30 month clock | 10 |
| Ezetimibe | Oral | Tablet 10 mg | $10.83 | 23.54% | $8.28 | $9.57 | 13.48% | GWAPD | 10 |
| Fluorouracil | Injection | Injection 2500 mg in 50 mL | $17.73 | 31.70% | $12.11 | $17.73 | 31.70% | OWAPD | 30 |
| Fluorouracil | Injection | Injection 500 mg in 10 mL | $3.55 | 31.70% | $2.42 | $3.55 | 31.83% | OWAPD | 30 |
| Fluorouracil | Injection | Injection 5000 mg in 100 mL | $35.46 | 31.70% | $24.22 | $35.46 | 31.70% | OWAPD | 30 |
| Hyoscine | Injection | Injection containing hyoscine butylbromide 20 mg in 1 mL | $10.03 | 34.53% | $6.57 | $8.79 | 25.26% | GWAPD | 10 |
| Lurasidone | Oral | Tablet containing lurasidone hydrochloride 40 mg | $46.48 | 17.04% | $38.56 | $46.48 | 17.04% | Does not meet 30 month clock | 10 |
| Lurasidone | Oral | Tablet containing lurasidone hydrochloride 80 mg | $92.96 | 17.04% | $77.12 | $92.96 | 17.04% | Does not meet 30 month clock | 10 |
| Moxonidine | Oral | Tablet 200 micrograms | $6.36 | 10.87% | $5.67 | $6.36 | 10.85% | GWAPD | 10 |
| Moxonidine | Oral | Tablet 400 micrograms | $10.84 | 10.87% | $9.66 | $10.84 | 10.89% | GWAPD | 10 |
| Nebivolol | Oral | Tablet 1.25 mg (as hydrochloride) | $14.73 | 20.15% | $11.76 | $14.73 | 20.16% | GWAPD | 10 |
| Nebivolol | Oral | Tablet 10 mg (as hydrochloride) | $41.56 | 20.15% | $33.19 | $41.56 | 20.14% | GWAPD | 10 |
| Nebivolol | Oral | Tablet 5 mg (as hydrochloride) | $36.78 | 20.15% | $29.37 | $36.78 | 20.15% | GWAPD | 10 |
| Nevirapine | Oral | Tablet 200 mg | $102.33 | 30.13% | $71.50 | $102.33 | 30.13% | GWAPD | 30 |
| Nevirapine | Oral | Tablet 400 mg (extended release) | $102.33 | 30.13% | $71.50 | $102.33 | 30.13% | GWAPD | 30 |
| Pegfilgrastim | Injection | Injection 6 mg in 0.6 mL single use pre-filled syringe | $346.39 | 48.56% | $178.18 | $346.39 | 48.56% | GWAPD | 30 |
| Posaconazole | Oral | Tablet (modified release) 100 mg | $407.89 | 24.15% | $309.38 | $407.89 | 24.15% | Does not meet 30 month clock | 10 |
| Rituximab | Injection | Solution for I.V. infusion 100 mg in 10 mL | $310.53 | 56.23% | $135.92 | $216.17 | 37.12% | Does not meet 30 month clock | 10 |
| Rituximab | Injection | Solution for I.V. infusion 500 mg in 50 mL | $776.32 | 56.23% | $339.80 | $540.43 | 37.12% | Does not meet 30 month clock | 10 |
| Tenofovir with emtricitabine | Oral | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | $53.81 | 34.77% | $35.10 | $53.81 | 34.77% | OWAPD | 30 |
| Tenofovir with emtricitabine | Oral | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | $53.81 | 34.77% | $35.10 | $53.81 | 34.77% | OWAPD | 30 |
| Tenofovir with emtricitabine | Oral | Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg | $53.81 | 34.77% | $35.10 | $53.81 | 34.77% | OWAPD | 30 |
| Tenofovir with emtricitabine | Oral | Tablet containing tenofovir disoproxil succinate 301 mg with emtricitabine 200 mg | $53.81 | 34.77% | $35.10 | $53.81 | 34.77% | OWAPD | 30 |
| Tenofovir with emtricitabine and efavirenz | Oral | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg and efavirenz 600 mg | $270.88 | 13.69% | $233.80 | $270.88 | 13.69% | Does not meet 30 month clock | 10 |
| Trastuzumab | Injection | Powder for I.V. infusion 150 mg | $375.39 | 36.86% | $237.02 | $315.26 | 24.82% | Does not meet 30 month clock | 10 |
| Trastuzumab | Injection | Powder for I.V. infusion 420 mg | $1,051.09 | 36.86% | $663.66 | $882.71 | 24.82% | Does not meet 30 month clock | 10 |
| Zoledronic acid | Injection | Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL | $72.80 | 30.99% | $50.24 | $72.80 | 30.99% | GWAPD | 30 |
| Zoledronic acid | Injection | Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL | $72.80 | 30.99% | $50.24 | $72.80 | 30.99% | GWAPD | 30 |
| Zoledronic acid | Injection | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | $97.47 | 30.99% | $67.26 | $97.47 | 30.99% | GWAPD | 30 |
Confirmed prices of brands scheduled for a price disclosure reduction
The Confirmed Prices Report outlines the approved ex-manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2022 April cycle can be downloaded below.